NKGNW NKGen Biotech, Inc. Warrants

97

Health Care [ 12/12 ] | Biotechnology [ 64/73 ]

NASDAQ | Common Stock

Price
$0.04
Decreased by -64.33%
Dollar volume (20D)
1.21 K
ADR%
47.00
Shares float
17.82 M
Shares short
1.53 K [0.01%]
Shares outstanding
0.00
Market cap
N/A
Beta
0.45
Price/earnings
N/A
20D range
0.03 0.15
50D range
0.01 0.15
200D range
0.01 0.29

NKGen Biotech, Inc. operates as a clinical-stage biotechnology company that focuses on the development and commercialization of autologous, allogeneic, and CAR-NK natural killer cell therapies.

Its lead products include SNK01, an autologous NK cell therapy candidate treatment for neurodegenerative diseases; and SNK02, an allogeneic NK cell therapy, which is in Phase 1 clinical trials for refractory solid tumors.

The company has a license agreement with NKMAX.

The company was formerly known as NKMAX America, Inc. NKGen Biotech, Inc. was founded in 2017 and is headquartered in Santa Ana, California.

  • Quarterly earnings
  • Annual earnings
Reported date EPSChange YoY EstimateSurprise
  • Quarterly financials
  • Annual financials
Fiscal ending date RevenueChange YoY IncomeChange YoY ProfitChange YoY
Sep 30, 23 0.00 - -33.18 M -
Decreased by N/A%
-
Dec 31, 22 0.00 - -6.95 M -
Decreased by N/A%
-
Sep 30, 22 3.00 K - -6.69 M -
Decreased by -223.10 K%
-
Open dropdown content
Open dropdown content
DAILY
WEEKLY
MONTHLY